Keith brings nearly 20 years of experience in developing and commercializing oncology diagnostics, including companion diagnostics (CDx). Prior to his role at Blueprint Medicines, he served as the commercial lead for LabCorp’s Oncology division, Integrated Oncology. During this time, he led a range of focus areas spanning the drug and diagnostic development continuum. Prior to this, he served in a variety of roles including diagnostics sales and marketing (both on the diagnostics and oncology therapeutics side) and obtained his MBA at NYU, Stern School of Business.
Winning FDA Approval for GIST Precision Therapy
Precision medicine continues to make rapid advances in oncology – with multiple therapies falling under breakthrough therapy designation, real-time review and pan-cancer indications. This talk will focus on the opportunities and challenges faced by biopharmaceutical companies and precision medicine stakeholders through the lens of Blueprint Medicines clinical portfolio.